Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427102 | 0.98 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4119981 | 0.98 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL31648685 | 0.83 | JAK2 (0.35) | CA1CA2CA7CA9CA12 | |
| SCHEMBL6559354 | 0.81 | ALDH1A1 (0.40) | CA1CA2CA7CA9CA12 | |
| SCHEMBL146841 | 0.80 | CA1 (0.61) | CA1CA2CA7CA9CA12 | |
| SCHEMBL971122 | 0.78 | CA1 (0.60) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29588385 | 0.77 | CA1 (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7101270 | 0.77 | CA1 (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7930018 | 0.76 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL1829968 | 0.76 | NQO2 (0.44) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599920-B2 | Antiestrogenic compound having fewer or no estrogen agonist properties on reproductive tissues | ELI LILLY AND COMPANY | 2003-07-29 | — | — | US | disclosed |
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-0826670-B1 | Naphthalene compounds, intermediates, formulations, and methods | LILLY CO ELI (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-0826680-B1 | Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods of preparation thereof. | LILLY CO ELI (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6020513-A | BONE DISORDERS | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| US-5958916-A | FOR INHIBITING BONE LOSS OR BONE RESORPTION | ELI LILLY AND COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0826680-A1 | Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
| EP-0826670-A1 | Naphthalene compounds, intermediates, formulations, and methods | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | NDC1, SQLE, NQO1 | CA1 3697/4885CA2 2725/4885CA7 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.